Comprehensive circulating tumor DNA (ctDNA) profiling in treatment-naïve early-stage breast cancer patients identified metastatic-associated genomic signatures detectable through liquid biopsy.
Early detection of tumor-derived genomic alterations in plasma ctDNA revealed molecular indicators linked to increased risk of disease progression.
ctDNA analysis captured tumor heterogeneity and early genomic events that may not always be detected through conventional tissue biopsies.
Plasma-based genomic profiling enables non-invasive assessment of tumor mutation patterns, supporting precision oncology diagnostics.
Identification of metastatic risk signatures through ctDNA-based liquid biopsy may help clinicians stratify patients according to progression risk.
Early molecular detection of high-risk genomic alterations may support proactive therapeutic intervention and personalized treatment planning.
Longitudinal ctDNA monitoring allows real-time tracking of tumor evolution, treatment response, and emerging resistance mechanisms.
Overall, ctDNA-driven genomic profiling offers a powerful approach for risk stratification, disease monitoring, and precision management in early-stage breast cancer.
Read Abstract